Bonus Episode: c-Met Protein Overexpression as an Emerging Biomarker in NSCLC - European Medical Journal

Bonus Episode: c-Met Protein Overexpression as an Emerging Biomarker in NSCLC

Oncology

The EMJ Podcast | Bonus Episode

Listen to our latest bonus EMJ podcast episode, featuring an expert discussion on c-Met protein overexpression as an emerging biomarker in non-small cell lung cancer (NSCLC).

Featuring Jair Bar, Deputy Director of the Institute of Oncology, Sheba Medical Center, Ramat Gan, Israel, and Adam Januszewski, Medical Consultant at Barts Health NHS Trust, London, UK.
Topics of discussion include:
  • the prevalence of MET aberrations in NSCLC;
  • prognostic implications of MET aberrations;
  • the rationale for targeting c-Met protein overexpression with novel therapies; and the use of antibody-drug conjugates to target c-Met protein expression
This podcast is organised and funded by AbbVie. It was developed in collaboration with EMJ. This podcast has been approved for HCP-audiences only and has not been approved for distribution to United Kingdom healthcare professionals.  The views expressed in this podcast are those of the individual speakers and do not necessarily reflect the views of AbbVie.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given